In Japan, the generic drug market is characterized on one side by increasingly wider availability of generic drugs and on the other by intensifying competition, due to the entry of new participants into this market, and progressively more extensive industry realignment.
To chart a route through this business landscape, Fuji Pharma is following the roadmap laid out in its 2014 Medium-term Business Plan, which highlights three objectives: 1) achieve a higher profile in selected disease domains by focusing on new injection agents; 2) establish Fuji Pharma as a leading company in the field of medical care for women; and 3) build a new operating framework for success through the next 50 years. As we work toward these objectives, we will define our strengths and raise our profile by executing more effective investment of management resources and enhancing business value. With consistently stable growth, we will leap well beyond our domestic borders and establish a firm position in the global market.
Our corporate cornerstone embodies management philosophies aimed at "contributing to healthy living by supplying outstanding pharmaceuticals" and "growth of the Company that is directly proportional to the growth of its employees." We seek to deepen our level of contribution and growth, and the ongoing support of our efforts by all stakeholders, including shareholders, employees, communities and society as a whole, is essential to this process. On behalf of the Board, I thank you for the part you play in our success and ask for your continued involvement.